Patients randomised to IV abatacept ( 10 or 2 mg/kg ) or placebo , plus MTX , during the 1-year double-blind ( DB ) period of a Phase 2b study could enter the long-term extension ( LTE ) and receive IV abatacept 10 mg/kg monthly .